Chinese Covid vaccine wins patent approval

Tianjin-based vaccine producer, CanSino Biologics, has won patent approval for its Ad5-nCOV vaccine candidate. The Covid-19 vaccine was approved in Beijing on 11 August, Chinese state-owned media reported citing documents released by China’s Intellectual Property Administration. The Ad5-nCOV candidate was co-developed by CanSino Biologics and a team of infectious disease experts, led by Chen Wei,…